<DOC>
	<DOCNO>NCT00798785</DOCNO>
	<brief_summary>The present proof concept study address follow specific aim : The general objective work : 1 . To increase maintain functional beta-cell mass islet transplantation condition low-dose tacrolimus 2 . To co-investigate potential alternative site encapsulate beta-cells</brief_summary>
	<brief_title>Long-term Function Beta Cell Allografts Non-uremic Type 1 Diabetic Patients</brief_title>
	<detailed_description>1 . Aim 1 : To increase functional beta cell mass add rituximab first implantation 2 . Aim 2 : To increase functional beta cell mass add basilixumab second implantation 3 . Aim 3 : To assess influence down-tapering tacrolimus dose posttransplant year 2-5 data , metabolic control , prevalence hypoglycemia safety parameter . 4 . Aim 4 : To investigate potential peritoneum omentum alternative site encapsulate beta-cells . 5 . Aim 5 : To investigate potential brachioradial muscle alternative site encapsulate beta-cells .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age 1865 year , male female , Caucasian ; subject &lt; 50 yr allocate rituximab treatment arm Body weight &lt; 100 kg ; patient bodyweight &lt; 80kg , receive priority Patients BMI ≤ 27 kg/m2 receive priority Type 1 insulindependent diabetes Cpeptide &lt; 0.07 nmol/l ( &lt; 0.2 µg/l ) 6 min . glucagon IV ( 1mg ) ( glycemia &gt; 180 mg/dl ) Intensive insulin therapy two year , patient insulin pump least 2 month inclusion receive priority Patients least one follow chronic complication diabetes : Plasma creatinine &lt; 2 mg/dl albuminuria 301000 mg/ 24hrs 3 separate determination ( &gt; 1 month ) outside episode illness , despite intake ACE inhibitor ; mean systolic blood pressure 130 mmHg mean diastolic blood pressure 85 mmHg , measure home ambulatory BP monitoring Moderate severe nonproliferative proliferative retinopathy Hypoglycemic unawareness Cooperative reliable patient give informed consent signature Smoker EBV antibody negativity HIV 1 &amp; 2 antibody positivity CMV IgM positivity Plasma creatinine ≥ 2 mg/dl and/or albuminuria ≥1000 mg/24 hr History thrombosis pulmonary embolism History malignancy , tuberculosis chronic viral hepatitis History serious illness could relevant protocol Presence HLA antibody Blood donation within one month prior screen study Symptoms and/or sign infection , particularly ( present past ) endocarditis , osteomyelitis , past tuberculosis requirement therapy Any history hepatic neoplastic disease Any history renal disease ( except diabetes ) Abnormal liver function test /or NMR liver Hemoglobinopathy History illness , opinion investigator , might confound result study pose additional risk patient Pregnancy use inadequate contraception female patient childbearing potential Use illicit drug overconsumption alcohol ( &gt; 3 beers/day ) history drug alcohol abuse Being legally incapacitate , significant emotional problem time study , history psychiatric disorder Having receive antidepressant medication last 6 month Having participate last 12 month participate another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>diabetes mellitus type 1</keyword>
	<keyword>pancreatic beta cell</keyword>
	<keyword>transplantation</keyword>
</DOC>